FDA Clearance Tracker · P170024-S010
Surpass Streamline Flow Diverter
Last checked: Nov 20, 2026Latest source record: Aug 5, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Aug 5, 2022
Approved
Time to decision
291 days
Received Oct 18, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P170024-S010
- Device name
- Surpass Streamline Flow Diverter
- Applicant
- Stryker Neurovascular
- Applicant location
- Fremont, CA
- Received
- Oct 18, 2021
- Decided
- Aug 5, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P170024
Device type
- Device type
- Intracranial aneurysm flow diverter (OUT)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for labeling changes to incorporate completed results from the post-approval study (PAS) titled Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT).
Source documents
Other decisions for Stryker Neurovascular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261649 · Decided Oct 9, 2026 · 143 days after receipt
Device type: Catheter, Percutaneous, Neurovasculature (QJP) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.